The Pune-based Serum Institute of India (SII) is likely to start phase III trials of the second COVID-19 vaccine “Covovax”, which it is making in partnership with American company “Novavax”, by May 15.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkNoPrivacy policy
